Medicare will be covering use of Myriad's BracAnalysis companion diagnostic in men with prostate cancer who may be eligible for treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza).
Lynparza is approved for patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. BRCA testing in prostate cancer has been gaining steam with the approval of new indications for Lynparza (Merck/AstraZeneca) and other PARP inhibitors for this tumor type, building on the original approved use for treatment of ovarian cancer.
